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Abstract
Background: The malignant transformation of precancerous colorectal lesions involves progressive alterations at
both the molecular and morphologic levels, the latter consisting of increases in size and in the degree of cellular
atypia. Analyzing preinvasive tumors of different sizes can therefore shed light on the sequence of these alterations.
Methods: We used a molecular pathway-based approach to analyze transcriptomic profiles of 59 colorectal
tumors representing early and late preinvasive stages and the invasive stage of tumorigenesis. Random set analysis
was used to identify biological pathways enriched for genes differentially regulated in tumors (compared with
59 samples of normal mucosa).
Results: Of the 880 canonical pathways we investigated, 112 displayed significant tumor-related upregulation or
downregulation at one or more stages of tumorigenesis. This allowed us to distinguish between pathways whose
dysregulation is probably necessary throughout tumorigenesis and those whose involvement specifically drives
progression from one stage to the next. We were also able to pinpoint specific changes within each gene set that
seem to play key roles at each transition. The early preinvasive stage was characterized by cell-cycle checkpoint
activation triggered by DNA replication stress and dramatic downregulation of basic transmembrane signaling
processes that maintain epithelial/stromal homeostasis in the normal mucosa. In late preinvasive lesions, there was
also downregulation of signal transduction pathways (e.g., those mediated by G proteins and nuclear hormone
receptors) involved in cell differentiation and upregulation of pathways governing nuclear envelope dynamics and
the G2>M transition in the cell cycle. The main features of the invasive stage were activation of the G1>S transition
in the cell cycle, upregulated expression of tumor-promoting microenvironmental factors, and profound
dysregulation of metabolic pathways (e.g., increased aerobic glycolysis, downregulation of pathways that
metabolize drugs and xenobiotics).
Conclusions: Our analysis revealed specific pathways whose dysregulation might play a role in each transition of
the transformation process. This is the first study in which such an approach has been used to gain further insights
into colorectal tumorigenesis. Therefore, these data provide a launchpad for further exploration of the molecular
characterization of colorectal tumorigenesis using systems biology approaches.
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Background
Colon carcinogenesis is a multistep process involving
the gradual accumulation of genetic and epigenetic
alterations. These changes promote the malignant trans-
formation of precancerous lesions of the colorectal mu-
cosa [1], a process reflected by progressively severe
cellular dysplasia and increases in lesion size. At least
two-thirds of all colorectal cancers develop from pre-
cancerous lesions with adenomatous features [2]. The
“serrated” histotype characterized by cells arranged in a
saw-toothed pattern [1] is somewhat less common, but
in both cases, size is an important indicator of the dis-
tance the lesion has travelled on the road toward malig-
nancy. For this reason, post-polypectomy surveillance
guidelines vary depending in part on the size of the
polyps removed. In fact, individuals with 3 or more ad-
enomas on initial colonoscopy, including 1 or more
measuring ≥10 mm, are significantly more likely to
present with new lesions at the next colonoscopy [3].
Analysis of precancerous colorectal lesions of different
sizes can thus furnish important information on the
steps involved in their malignant transformation. During
colonoscopy, benign lesions of all sizes are routinely
removed to prevent their progression toward cancer, and
this provides a valuable source of tissues for molecular
studies. Efforts of this type have already identified sev-
eral genetic and epigenetic changes that seem to occur
at the transition from normal mucosa to precancerous
lesions. Mutations involving the APC or CTNNB1 gene,
for example, are considered early events that fuel
epithelial-cell proliferation [4,5]. Gain-of-function muta-
tions in the oncogenes KRAS and BRAF are also fre-
quent findings in early stages of transformation [6].
Additional alterations (genetic and epigenetic) are
believed to be necessary for subsequent steps toward
invasiveness, such as those identified with recent
genome-wide analyses [7,8].
The transcriptomes of colorectal cancers have been
intensively investigated with high-throughput, array-
based tools, which furnish quantitative, genome-wide
descriptions of the individual gene expression levels
associated with different cell phenotypes (e.g., adenoma
cells vs. normal epithelial cells) [9-12]. More recently,
other methods of analyzing gene expression data have
been developed to gain additional insight into the
mechanisms driving the phenotypic differences. One
such approach involves the analysis not of single genes
but of predefined functional gene sets, that is, groups of
genes that are known components of a defined mole-
cular pathway representing a given biological process.
The basic aim here is to identify those gene sets
(i.e., pathways) that display enrichment for―or over-
representation of― genes whose expression is sub-
stantially altered in the phenotype being investigated.
We have explored several methods for quantitatively
analyzing transcriptomic data for pathway enrichment
[13-15], including gene set enrichment analysis (GSEA)
[16], random-set methods (RS) [17], and gene list ana-
lysis with prediction accuracy (a method developed by
our group) [15]. Although these methods differ sub-
stantially from one another, all three are statistically
accurate and identify relevant gene sets, and none con-
sistently outperforms the others [14].
Our experience indicates that pathway-based analysis
of gene expression data furnishes highly reproducible
results that can be useful for dissecting a complex, poly-
genic disease like colorectal cancer. For instance, we re-
cently used GSEA and RS analysis to identify pathway
enrichment in four independent transcriptional data sets
representing colorectal cancer and normal mucosa. The
results of these analyses displayed substantial overlap:
both of the analytical methods used revealed similar dys-
regulation of 53 pathways in each of the four data sets.
These pathways are very likely to play important roles in
the pathology of colorectal cancer [13].
In the present study, we used RS analysis to explore a
large body of previously collected transcriptomic data on
human colorectal tissues, including normal mucosa, pre-
invasive lesions of various sizes, and colorectal cancers
(CRCs). Our aim was to identify biological processes that
become dysregulated during the course of colorectal
tumorigenesis. Because the preinvasive stages have been
far less extensively explored than the cancerous phases
of this process, there were no independent sets of tran-
scriptomic data on precancerous lesions that we could
use to validate our findings. To overcome this limitation,
we used two strategies. First, we re-analyzed all the ori-
ginal data sets with GSEA and compared the results with
those obtained with RS. Second, we performed RS ana-
lysis of two publicly available sets of data on CRCs and
normal colorectal mucosa.
Methods
All data were analyzed in MatLab (MathWorks, Natick,
MA) unless otherwise stated.
Data set
The data set analyzed in this study consisted of the tran-
scriptome profiles of a series of 118 human colorectal
tissues (details below) analyzed with the GeneChip
Human Exon 1.0 ST array (Affymetrix, Santa Clara, CA,
USA). Raw microarray data are available in GEO
(GSE21962 [18]) and ArrayExpress (E-MTAB-829).
In brief, arrays were analyzed in the Affymetrix Gene-
Chip Scanner 3000 7 G. Cell intensities were measured
with Affymetrix GeneChip Operating Software, and
Affymetrix Expression Console Software was used for
quality assessment: probe expression intensity in each
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tissue sample was subjected to background adjustment
and normalization with the Robust Multi-array Analysis
algorithm.
The tissues themselves had been prospectively col-
lected during colonoscopy (precancerous lesions) or sur-
gery (cancers). They consisted of 59 tumor specimens,
each accompanied by a sample of normal mucosa col-
lected in the same colon segment >2 cm from the lesion.
The fragment used for microarray analysis (~20 mg of
epithelial tissue) was cut from each specimen immedi-
ately after removal, leaving the underlying muscularis
mucosae intact, and the remaining tissue was submitted
for pathologic analysis. (We used only lesions measuring
>1 cm to ensure that our sampling procedure would not
interfere with the histologic diagnosis.) All tumors were
sporadic lesions with a functional DNA mismatch repair
system. As expected, LPLs were more likely to exhibit
villous changes (43.5% vs. 36.8% of the SPLs) and high-
grade dysplasia (34.8% vs. 10.5% of the SPLs).
For the purposes of the present study, we divided the
gene expression data into four subsets representing suc-
cessive stages of colorectal tumorigenesis: 19 small pre-
invasive lesions (SPLs) measuring 11–20 mm in
diameter, 23 large preinvasive lesions (LPLs) with dia-
meters > 20 mm, and 17 CRCs (Table 1). A fourth set
was created with data for all 59 normal mucosal (N)
samples. The 20-mm cutoff for SPLs was chosen in part
to obtain two similarly sized subgroups (for statistical
purposes) and in part because our previous observations
[18] suggested such subgroups are likely to present bio-
logical differences. All of the preinvasive lesions were ad-
enomas except five, which exhibited serrated histology.
These five lesions were included since they did not be-
have as outliers in Principal Component Analysis (PCA),
and their exclusion did not significant alter the data
reported in this study.
The study was carried out according to the principles
of the Declaration of Helsinki and was approved by the
Ethics Committees of the Italian hospitals where the tis-
sues were collected (Istituti Ospitalieri, Cremona, and
Casa Sollievo della Sofferenza, San Giovanni Rotondo,
Italy). Each subject investigated provided written
informed consent to collection and analysis of data and
publication of the findings.
Gene sets
Our analyses focused on 880 functional gene sets from
the CP-C2 collection in the Molecular Signatures
Database (MSigDB), version 3.0 [16]. These canonical
representations of biological pathways or processes
have been compiled by domain experts and curated
from several online databases (BioCarta, Gene Arrays,
BioScience Corp, KEGG, Reactome, Sigma-Aldrich
Pathways, Signal Transduction Knowledge Environ-
ment, Signaling Gateway).
Statistical methods
The RS method was used to identify tumor-associated
pathway enrichment. In brief, a pathway-level statistic is
used to average differential-expression evidence across
all genes (e.g., gene-level scores) in a given pathway
(gene set C containing n distinct genes). The enrichment
of pathway C for differentially expressed genes is then
measured by comparing C with other hypothetical gene
sets made up of the same number (n) of genes randomly
selected from the array. RS analysis can be used with a
variety of gene-level scores. In this case, we used the
rank of two-sample t-test values of genes in the array
[13,14]. The mean and variance of the RS score distribu-
tion can be analytically derived, and the induced distri-
bution is approximately Gaussian. This offers an easily
computed standardized statistic for measuring pathway
enrichment. The RS method has several practical advan-
tages, including high computation efficiency [14], an ex-
tremely important feature when large numbers of
experiments have to be performed.
For each gene set considered in our analysis, the distri-
bution of the component gene expression levels in the N
data subset was independently compared with that of
each of the stage-specific tumor subsets (i.e., N vs. SPL,
N vs. LPL, and N vs. CRC). In each case, the difference
was calculated to quantify tumor-related upregulation or
downregulation of the pathway (reflected by positive
and negative RS scores, respectively) at that stage of
tumorigenesis.
The statistical significance of the RS enrichment score
was assessed with non-parametric permutation tests
[19]. For this purpose, we computed the nominal p-
value of each score by comparing the actual score with
the empirical probability density function under the null
hypothesis (no genotype-phenotype association) derived
using 1000 permutations of the phenotypic labels (0=N,
1=tumor, i.e., SPL, LPL, or CRC lesions). A p-value cut-
off of 0.05 was used to define significant pathway
enrichment.
Expression data for genes in the Biocarta cell cycle
pathway were also subjected to hierarchical clustering
analysis and PCA to confirm the relevance of our
results. For the former analysis, a Euclidean distance
metric and inner squared distance linkage were used to
generate hierarchical trees. We analyzed three multi-
dimensional data sets, each representing normal mucosa
and a given stage of tumor, and clustered heat maps
were shown. PCA was applied to the entire multi-
dimensional data set representing normal mucosa and
tumors of all stages. Each tissue sample was then
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projected onto the first two principal components to
create a 2-dimensional map of the data set.
The validation procedure involved the use of standard
GSEA [16], and p-values for the enrichment scores were
computed on the basis of 1000 label permutations.
Results and discussion
As shown in Tables 2 and 3, a total of 64 pathways were
found to be significantly upregulated (n=23) or downre-
gulated (n=41) in SPLs; 50 were upregulated (n=21) or
downregulated (n=29) in LPLs; and 58 were upregulated
(n=33) or downregulated (n=25) in the CRCs. The ap-
proach we used allows in-depth exploration of each in-
stance of pathway dysregulation to characterize its
evolution across the transformation process. Because
Table 1 Characteristics of the 59 colorectal tumors
included in the study data set
Preinvasive lesions
Patient Age Sex Colon
segment
Diameter
(mm)
Stage† Histologic
grade ‡
Early stage (SPLs, diameters: 11–20 mm)
13b * 54 F Ascending 12 IIa TA (low)
21 66 M Ascending 12 IIa MVSP (none)
27 83 M Sigmoid 12 Ip TVA (low)
8 48 M Hepatic
flexure
15 IIa TA (low)
15 62 F Ascending 15 IIa SA (low)
16 52 F Transverse 15 IIa SSA (none)
22 64 F Ascending 15 Ip TA (low)
23 56 M Ascending 15 Ip TA (low)
25 27 M Ascending 15 Ip TVA (high)
35 69 F Sigmoid 15 Ip TVA (low)
36 58 F Ascending 15 Ip TVA (low)
1b * 75 F Transverse 20 IIa VA (high)
2b * 72 F Transverse 20 IIa TA (low)
6 79 F Ascending 20 IIa TA (low)
7 67 F Ascending 20 IIa TA (low)
24 79 M Ascending 20 Ip TVA (low)
29 74 F Sigmoid 20 Ip TVA (low)
33 58 F Descending 20 Ip TA (low)
17b * 54 F Ascending 20 IIa TA (low)
Late-stage (LPLs, diameters: > 20 mm)
10 83 M Ascending 25 IIa TA (low)
11 66 M Cecum 25 IIa TA (high)
18 72 M Ascending 25 IIa TA (low)
19a * 79 M Ascending 25 IIa VA (low)
20 47 M Ascending 25 IIa-IIc MVSP (none)
2a * 72 F Cecum 30 IIa TA (low)
26 40 F Sigmoid 30 Ip TVA (low)
28 50 M Sigmoid 30 Ip TVA (high)
31 69 M Sigmoid 30 Ip TA (low)
32 56 M Sigmoid 30 Ip TA (low)
34 52 F Sigmoid 30 Ip TA (low)
19b * 79 M Transverse 30 Ip VA (low)
37 73 M Ascending 30 Ip TVA (high)
5 44 M Hepatic
flexure
35 IIa TA (low)
12 79 M Ascending 35 IIa-IIc TVA (high)
3 75 F Transverse 40 IIa-IIc TA (high)
4 73 F Ascending 40 IIa-IIc SA (high)
9 69 F Ascending 40 IIa TVA (low)
30 69 M Rectum 40 Ip TA (low)
Table 1 Characteristics of the 59 colorectal tumors
included in the study data set (Continued)
13a * 54 F Cecum 45 IIa TVA (low)
14 74 F Cecum 50 IIa TVA (low)
17a * 54 F Cecum 50 IIa TA (high)
1a * 75 F Transverse 70 IIa-IIb VA (high)
Invasive lesions (CRCs)
Patient Age Sex Colon
segment
Stage § Histologic
grade §
38 58 F Ascending T3N0 G2
39 81 M Transverse T2N0 G2
40 61 M Sigmoid T3N1 G2
41 69 F Descending T4N2 G3
42 77 M Sigmoid T2N0 G2
43 67 M Sigmoid T3N2 G2
44 67 M Sigmoid T3N1 G2
45 57 M Sigmoid T3N0 G2
46 81 F Sigmoid T2N0 G2
47 77 M Descending T3N1 G2
48 73 F Cecum T3N1 G3
49 57 M Sigmoid T3N0 G2
50 55 M Descending T3N0 G2
51 90 F Cecum T3N0 G2
52 80 F Ascending T3N1 G2
53 75 F Ascending T3N0 G2
54 77 F Cecum T3N0 G2
* Two lesions were analyzed from this patient.
† Paris Endoscopic Classification of Superficial Neoplastic Lesions (Gastrointest
Endoscopy 2003;58[suppl.]:S3-S27).
‡ Preinvasive lesions were classified as tubular adenomas (TA), tubulovillous
adenomas (TVA), villous adenomas (VA), microvescicular serrated polyps
(MVSP), serrated adenomas (SA), sessile serrated adenomas (SSA). In
parentheses, the degree of dysplasia (none, low, high) is reported based on
the WHO classification of tumors of the digestive system (Editorial and
consensus conference in Lyon, France, November 6–9, 1999 [IARC]).
§ Sobin LH, Wittekind C. TNM classification of malignant tumours. 6th ed.
New York, NY: Wiley-Liss, 2002.
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Table 2 Biological pathways displaying up-regulation (versus normal mucosa) in SPLs, LPLs, and CRCs
Nominal p-values of enrichment scores †
Pathways n * N vs SPL N vs LPL N vs CRC
1) KEGG BASE EXCISION REPAIR 48 0.042 - -
2) KEGG HOMOLOGOUS RECOMBINATION 34 0.043 - -
3) REACTOME ACTIVATION OF THE PRE REPLICATIVE COMPLEX 35 0.047 - -
4) REACTOME HOMOLOGOUS RECOMBINATION REPAIR 22 - 0.048 -
5) BIOCARTA CELLCYCLE PATHWAY 32 - - 0.025
6) BIOCARTA MONOCYTE PATHWAY 20 - - 0.035
7) BIOCARTA P27 PATHWAY 14 - - 0.025
8) BIOCARTA RB PATHWAY 20 - - 0.047
9) BIOCARTA SET PATHWAY 15 - - 0.034
10) BIOCARTA SKP2E2F PATHWAY 12 - - 0.014
11) KEGG RNA POLYMERASE 27 - - 0.04
12) REACTOME AMINO ACID TRANSPORT ACROSS THE PLASMA MEMBRANE 40 - - 0.027
13) REACTOME CYTOSOLIC TRNA AMINOACYLATION 26 - - 0.031
14) REACTOME G1 PHASE 17 - - 0.03
15) REACTOME GLUCOSE TRANSPORT 55 - - 0.041
16) REACTOME GLYCOLYSIS 27 - - 0.039
17) REACTOME NEP NS2 INTERACTS WITH THE CELLULAR EXPORT MACHINERY 39 - - 0.049
18) REACTOME POST CHAPERONIN TUBULIN FOLDING PATHWAY 9 - - 0.034
19) REACTOME PREFOLDIN MEDIATED TRANSFER OF SUBSTRATE TO CCT TRIC 25 - - 0.027
20) REACTOME PROSTANOID HORMONES 15 - - 0.046
21) REACTOME RNA POLYMERASE III CHAIN ELONGATION 12 - - 0.033
22) REACTOME RNA POLYMERASE III TRANSCRIPTION INITIATION FROM TYPE 2 PROMOTER 21 - - 0.047
23) REACTOME TAT MEDIATED HIV1 ELONGATION ARREST AND RECOVERY 31 - - 0.049
24) REACTOME TRNA AMINOACYLATION 34 - - 0.048
25) REACTOME TRANSPORT OF RIBONUCLEOPROTEINS INTO THE HOST NUCLEUS 40 - - 0.043
26) REACTOME VPR MEDIATED NUCLEAR IMPORT OF PICS 48 - - 0.031
27) SA REG CASCADE OF CYCLIN EXPR 18 - - 0.01
28) BIOCARTA ARF PATHWAY 24 0.033 0.037 -
29) KEGG NUCLEOTIDE EXCISION REPAIR 48 0.031 0.043 -
30) KEGG ONE CARBON POOL BY FOLATE 19 0.004 0.032 -
31) REACTOME DUAL INCISION REACTION IN GG NER 18 0.032 0.025 -
32) REACTOME G2 M TRANSITION 80 0.038 0.035 -
33) REACTOME MITOCHONDRIAL TRNA AMINOACYLATION 11 0.032 0.04 -
34) REACTOME PURINE METABOLISM 42 0.037 0.03 -
35) REACTOME RNA POLYMERASE I CHAIN ELONGATION 29 0.021 0.026 -
36) REACTOME RNA POLYMERASE I PROMOTER ESCAPE 21 0.027 0.014 -
37) REACTOME RNA POLYMERASE I TRANSCRIPTION INITIATION 25 0.013 0.009 -
38) REACTOME RNA POLYMERASE I TRANSCRIPTION TERMINATION 22 0.027 0.013 -
39) REACTOME SNRNP ASSEMBLY 60 0.031 0.029 -
40) REACTOME MRNA DECAY BY 3 TO 5 EXORIBONUCLEASE 11 0.015 - 0.029
41) REACTOME RNA POLYMERASE III TRANSCRIPTION INITIATION 29 0.041 - 0.047
42) REACTOME NUCLEAR IMPORT OF REV PROTEIN 39 - 0.049 0.043
43) REACTOME REV MEDIATED NUCLEAR EXPORT OF HIV1 RNA 41 - 0.043 0.039
Maglietta et al. BMC Cancer 2012, 12:608 Page 5 of 16
http://www.biomedcentral.com/1471-2407/12/608
this process is progressive, it was not surprising to find
significant dysregulation of certain pathways in 2 or even
3 of the tumor stage-specific data sets, but other altera-
tions were more circumscribed (Figure 1). For example,
the BIOCARTA CELL CYCLE PATHWAY (Table 2, row
5) is one of the 23 gene sets that displayed significant
upregulation only in the CRCs. This gene set comprises
22 genes (32 RefSeqs) encoding cyclins, cyclin-
dependent kinases (CDK), cyclin-dependent kinase inhi-
bitors (CDKI), and transcription factors, including E2F1,
whose activation governs the G1-to-S phase transition of
the cell cycle. The tumor suppressor RB1 (retinoblast-
oma protein) negatively regulates cell cycling by com-
plexing with E2F1, and this effect is reversed by the
phosphorylation of RB1 by cyclin D/CDK4, cyclin D/
CDK6, and cyclin E/CDK2, which releases E2F1 from
this complex and allows cell cycling to resume. For
this reason, specific inhibitors of the cyclin/CDK com-
plexes, such as p15 (CDKN2B), p16 (CDKN2A), p21
(CDKN1A), and p27 (CDKN1B), are also considered
tumor suppressors. Dysregulation of this network stem-
ming (for example) from the overexpression of certain
cyclins, CDKs, or E2F1 itself, or from the down-
regulation of certain CDKIs, can lead to uncontrolled
cell growth, which favors tumor formation and progres-
sion [20-24].
Figure 2 (panels A, B, C) shows heat maps of the ex-
pression of the 22 genes included in the Biocarta cell
cycle pathway at each stage of tumorigenesis (compared
with normal mucosa). Each of the three tumor + N data
sets was subjected to hierarchical clustering analysis
using the 22 cell cycle-associated genes. As shown in
Figure 2A, this analysis identified two clusters within the
N vs. SPL data set, which showed no relation to the ac-
tual tissue labels (see column labels in Figure 2A). In the
N vs. LPL data set (Figure 2B), the two tissue-type
groups were more readily distinguished (only 6 LPL
samples were misclassified), and in the N vs. CRC set,
the two classes of tissues were separated with only three
errors. Collectively, these findings point to progressive
dysregulation of the cell cycle pathway, which becomes
overt in the invasive stage of tumorigenesis, as high-
lighted by our RS analysis. Major involvement of this
pathway at the CRC stage also emerged when the gene
expression profiles were subjected to PCA (Figure 2D).
As shown in Figures 3A and 3B, certain cell cycle
genes were already overexpressed in SPLs and LPLs, in-
cluding those encoding CCND1, CCND2, and CCNE1,
CDKs 2, 4, 6, and 7, and the oncogenes CDC25A and
TFDP1. These changes were associated with downregu-
lated transcription of the genes encoding the CDKI p15
(CDKN2B) and p21 (CDKN1A), an expected finding for
preinvasive lesions with high proliferation rates. In con-
trast, CDKI p27 (CDKN1B) expression was upregulated
in LPLs, but not CRCs (Figure 3C), a finding that is con-
sistent with previously reported immunostaining profiles
of adenomatous and cancerous colorectal tissues [25].
Interestingly, the tumor suppressor RB1 was also upre-
gulated across all stages of tumorigenesis (Figure 3),
whereas, in previous studies, this alteration has been
documented only in the malignant phases [26-28]. The
most convincing explanation proposed for the upregu-
lated expression of RB1 and p27 envisions these factors
as possible mediators of a homeostatic mechanism that
protects cells from the putatively toxic effects of exces-
sive cyclin, CDK, or E2F1 activity [25,28].
One of the most dramatic changes that characterized
the transition to CRC (Figure 3C) was an increase in the
expression of E2F1, the master regulator of the cell cycle
pathway. This alteration is well known in colorectal car-
cinomas [22,29], and it seems to be associated with
higher tumor stages and poorer prognoses in these can-
cers [30] and those of other organs as well [31-33]. Two
other important cell cycle genes, those encoding the
tumor suppressors p16 (CDKN2A) and the RB homolog
p107 (RBL1), were also upregulated in CRCs. The ex-
pression of p16 can be silenced during tumorigenesis by
gene promoter methylation, but this phenomenon is
largely confined to colorectal cancers with the hyper-
methylator phenotype and DNA mismatch repair
defects, which account for < 20% of all colorectal can-
cers [34-36]. We have found p16 overexpression in
~80% of the colorectal cancers we have studied over the
years (unpublished data). Like the p27 and RB1 upregu-
lation mentioned above (or that of RBL1, which exerts
inhibitory effects on E2F1-mediated trans-activation),
Table 2 Biological pathways displaying up-regulation (versus normal mucosa) in SPLs, LPLs, and CRCs (Continued)
44) BIOCARTA PTC1 PATHWAY 13 0.022 0.018 0.028
45) BIOCARTA RANMS PATHWAY 8 0.013 0.024 0.022
46) REACTOME CYCLIN A1 ASSOCIATED EVENTS DURING G2 M TRANSITION 19 0.038 0.034 0.026
47) REACTOME FORMATION OF TUBULIN FOLDING INTERMEDIATES BY CCT TRIC 18 0.044 0.039 0.011
48) REACTOME PURINE RIBONUCLEOSIDE MONOPHOSPHATE BIOSYNTHESIS 13 0 0.004 0.008
49) REACTOME REGULATION OF GLUCOKINASE BY GLUCOKINASE REGULATORY PROTEIN 42 0.044 0.031 0.044
* n = number of RefSeqs in the pathway.
† measured by RS analysis; only significant p-values (< 0.05) are shown.
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Table 3 Biological pathways displaying down-regulation
(compared with normal mucosa) in SPLs, LPLs, and CRCs
Nominal p-values of
enrichment scores †
Pathways n * N vs
SPL
N vs
LPL
N vs
CRC
1) BIOCARTA AT1R PATHWAY 50 0.047 - -
2) BIOCARTA BIOPEPTIDES PATHWAY 81 0.027 - -
3)BIOCARTA IL3 PATHWAY 20 0.044 - -
4) KEGG ALDOSTERONE REGULATED
SODIUM REABSORPTION
51 0.029 - -
5) KEGG CHEMOKINE SIGNALING
PATHWAY
216 0.042 - -
6) KEGG GAP JUNCTION 100 0.039 - -
7) KEGG MAPK SIGNALING
PATHWAY
400 0.047 - -
8) KEGG VASCULAR SMOOTH
MUSCLE CONTRACTION
152 0.037 - -
9) REACTOME FORMATION OF
PLATELET PLUG
236 0.017 - -
10) REACTOME FRS2 MEDIATED
ACTIVATION
23 0.049 - -
11) REACTOME HEMOSTASIS 348 0.024 - -
12) REACTOME METABOLISM OF
LIPIDS AND LIPOPROTEINS
256 0.046 - -
13) REACTOME NRAGE SIGNALS
DEATH THROUGH JNK
61 0.041 - -
14) REACTOME PLATELET
ACTIVATION
208 0.018 - -
15) REACTOME RHO GTPASE
CYCLE
132 0.046 - -
16) REACTOME SEMAPHORIN
INTERACTIONS
89 0.031 - -
17) SA PTEN PATHWAY 27 0.027 - -
18) REACTOME CAM PATHWAY 32 - 0.042 -
19) REACTOME G ALPHA Z
SIGNALLING EVENTS
13 - 0.04 -
20) REACTOME G BETA GAMMA
SIGNALLING THROUGH PLC BETA
23 - 0.037 -
21) REACTOME G PROTEIN
ACTIVATION
34 - 0.02 -
22) REACTOME NEURORANSMITTER
RECEPTOR BINDING AND
DOWNSTREAM TRANSMISSION
IN THE POSTSYNAPTIC CELL
115 - 0.035 -
23) BIOCARTA NUCLEARRS PATHWAY 22 - - 0.009
24) KEGG ASCORBATE AND
ALDARATE METABOLISM
19 - - 0.008
25) KEGG DRUG METABOLISM
CYTOCHROME P450
71 - - 0.017
26) KEGG DRUG METABOLISM
OTHER ENZYMES
51 - - 0.045
27) KEGG LONG TERM
POTENTIATION
94 - - 0.024
Table 3 Biological pathways displaying down-regulation
(compared with normal mucosa) in SPLs, LPLs, and CRCs
(Continued)
28) KEGG METABOLISM OF
XENOBIOTICS BY CYTOCHROME
P450
69 - - 0.018
29) KEGG NICOTINATE AND
NICOTINAMIDE METABOLISM
26 - - 0.047
30) KEGG PENTOSE AND
GLUCURONATE INTERCONVERSIONS
24 - - 0.009
31) KEGG NITROGEN METABOLISM 28 - - 0.024
32) KEGG RETINOL METABOLISM 59 - - 0.028
33) KEGG STARCH AND SUCROSE
METABOLISM
54 - - 0.014
34) REACTOME ACTIVATION OF
NMDA RECEPTOR UPON
GLUTAMATE BINDING AND
POSTSYNAPTIC EVENTS
62 - - 0.049
35) REACTOME ETHANOL
OXIDATION
8 - - 0.012
36) REACTOME
GLUCURONIDATION
15 - - 0
37) REACTOME MITOCHONDRIAL
FATTY ACID BETA OXIDATION
9 - - 0.039
38) REACTOME PHASE II
CONJUGATION
62 - - 0.036
39) BIOCARTA HDAC PATHWAY 44 0.022 0.041 -
40) KEGG GLYCOSPHINGOLIPID
BIOSYNTHESIS LACTO AND
NEOLACTO SERIES
37 0.041 0.037 -
41) REACTOME ACTIVATION OF
KAINATE RECEPTORS UPON
GLUTAMATE BINDING
37 0.022 0.01 -
42) REACTOME ADP SIGNALLING
THROUGH P2Y PURINOCEPTOR 1
31 0.01 0.01 -
43) REACTOME ADP SIGNALLING
THROUGH P2Y PURINOCEPTOR 12
24 0.028 0.021 -
44) REACTOME GLUCAGON
SIGNALING IN METABOLIC
REGULATION
42 0.046 0.028 -
45) REACTOME GLUCAGON
TYPE LIGAND RECEPTORS
39 0.042 0.036 -
46) REACTOME GS ALPHA
MEDIATED EVENTS IN GLUCAGON
SIGNALLING
30 0.015 0.012 -
47) REACTOME G BETA GAMMA
SIGNALLING THROUGH
PI3KGAMMA
30 0.034 0.027 -
48) REACTOME HORMONE
SENSITIVE LIPASE HSL MEDIATED
TRIACYLGLYCEROL HYDROLYSIS
18 0.045 0.042 -
49) REACTOME IONOTROPIC
ACTIVITY OF KAINATE RECEPTORS
14 0.049 0.018 -
50) REACTOME OTHER SEMAPHORIN
INTERACTIONS
25 0.005 0.005 -
51) REACTOME PLATELET
ACTIVATION TRIGGERS
73 0.028 0.047 -
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p16 upregulation might represent a negative feedback
mechanism aimed at preventing the G1-to-S transition
(although E2F1 can readily overcome a p16-mediated
G1 block) [37]. It is interesting to note that the trends
shown in Figure 3, which are based on our analysis of
transcript levels, are—on the whole—consistent with
published data on the corresponding gene products.
Closer inspection of Tables 2 and 3 shows that the
pathways exhibiting tumor-related downregulation were
generally larger (in terms of the total number of RefSeqs
they contained) than those that were upregulated in
tumor tissues (mean numbers of RefSeqs in the gene
sets: 69 vs. 27.9, respectively; p-value of one-tailed t-
test = 2.4 · 10-4). This finding might be related to the
fact that tumor-associated downregulation was often
seen in highly conserved pathways that govern normal
mucosa homeostasis (e.g., cell differentiation pro-
grams). Pathways of this type have been extensively
studied since the early days of molecular biology, and
a relatively large number of their gene components
have been identified. Consequently, the gene sets
representing these pathways are likely to be larger than
those of more specialized pathways, which have prob-
ably been less thoroughly explored. Nonetheless, it is
also possible that fundamental pathways and networks
are effectively larger as a result of relatively high-level
component redundancy, a feature that would increase
their robustness and versatility and ensure essential
cellular functions in normal tissues under a variety of
conditions.
Because the preinvasive stages of colorectal tumori-
genesis analyzed in our study have been far less exten-
sively explored than the cancerous phases, there were no
independent transcriptomic data sets for precancerous
lesions to use to validate our results. To overcome this
limitation, we used two different approaches.
First, we re-analyzed our three data sets (N vs. SPL, N
vs. LPL, and N vs. CRC) with GSEA [16], in a manner
similar to that used in previous studies by our group
[13]. Table 4 shows the numbers of pathways displaying
significant tumor-associated enrichment in the RS and
GSEA analyses. In all cases, a high percentage of the
pathways found to be significantly up- or down-
regulated in tumors (compared with normal mucosa)
Table 3 Biological pathways displaying down-regulation
(compared with normal mucosa) in SPLs, LPLs, and CRCs
(Continued)
52) REACTOME SIGNAL AMPLIFICATION 39 0.007 0.005 -
53) REACTOME THROMBIN SIGNALLING
THROUGH PROTEINASE ACTIVATED
RECEPTORS
28 0.019 0.016 -
54) REACTOME THROMBOXANE
SIGNALLING THROUGH TP RECEPTOR
26 0.007 0.003 -
55) KEGG GNRH SIGNALING PATHWAY 150 0.017 - 0.008
56) BIOCARTA STATHMIN PATHWAY 34 - 0.034 0.009
57) BIOCARTA PGC1A PATHWAY 37 0.005 0.011 0.008
58) KEGG PPAR SIGNALING PATHWAY 86 0.026 0.034 0.044
59) KEGG PROXIMAL TUBULE
BICARBONATE RECLAMATION
25 0.003 0.003 0.011
60) KEGG SULFUR METABOLISM 18 0.047 0.03 0.038
61) REACTOME NUCLEAR RECEPTOR
TRANSCRIPTION PATHWAY
78 0.005 0.006 0.006
62) REACTOME NUCLEOTIDE LIKE
PURINERGIC RECEPTORS
23 0.011 0.012 0.022
63) REACTOME P2Y RECEPTORS 18 0.009 0.01 0.036
* n = number of RefSeqs in the pathway.
† measured by RS analysis; only significant p-values (< 0.05) are shown.
Figure 1 Numbers of pathways displaying tumor-associated dysregulation at one or more stages of colorectal tumorigenesis. Venn
diagrams show the numbers of pathways that were significantly dysregulated―i.e., upregulated (A) or downregulated (B) with respect to
findings in normal mucosa (N)―in small precancerous lesions (SPLs), large precancerous lesions (LPLs), and colorectal carcinomas (CRCs).
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displayed the same trend in GSEA. (In both cases, a p-
value cut-off of 0.05 was used to define significant en-
richment.) For example, in the analysis of N vs. SPL data
set, GSEA confirmed the presence of significant tumor-
associated enrichment for 21 (91%) of the 23 pathways
identified as enriched by our RS analysis (p-values = 0
computed by Fisher’s exact test). The number of
enriched pathways identified by GSEA was always sub-
stantially higher than that obtained with RS analysis.
This finding reflects the fact that in GSEA the nominal
p-value of a pathway enrichment score is computed via
an empirical phenotype-based permutation test proced-
ure [16]. RS analysis uses a more stringent selection
process in which the actual enrichment score of each
pathway is compared with the scores obtained by the
permutation of labels—an approach similar to that used
in GSEA—and with the scores for sets composed of ran-
domly selected genes [17].
Second, we validated the findings regarding CRCs by
performing RS analysis of two publicly available, inde-
pendent transcriptomic data sets. The first (V-set I) had
been generated by Affymetrix HGU133A GeneChip ana-
lysis of 47 samples of human colorectal tissues (22 of
normal mucosa, 25 CRCs) and is accessible through the
ArrayExpress site (E-MTAB-57). The second (V-set II)
was obtained with GeneChip Human Exon 1.0 ST array
analysis of 20 paired CRC-normal mucosa samples [38].
The results of these validation analyses are shown in
Table 5. The vast majority of pathways exhibiting CRC-
related upregulation in the original N vs. CRC data set
were also significantly upregulated in V-set I (73%, p-
value = 1.1x10-16, Fisher’s exact test) and V-set II (82%,
p-value = 3.3x10-16, Fisher’s exact test). Lower but still
excellent degrees of overlap were also observed for the
pathways found to be downregulated in CRCs compared
with normal mucosa.
Figure 4 summarizes the most relevant tumor-related
pathway dysregulations at different stages of transform-
ation. Due to space constraints, only the upregulated
pathways (Table 2) are discussed below; those that were
downregulated (Table 3) are considered in detail in
Additional file 1.
Our data suggest that the early preinvasive phase of
colorectal tumorigenesis is characterized on the whole
by upregulated activity of pathways involved in DNA
replication and repair (i.e., KEGG BASE EXCISION
REPAIR, KEGG HOMOLOGOUS RECOMBIN-
ATION, REACTOME ACTIVATION OF THE PRE-
REPLICATIVE COMPLEX).These findingsareconsistent
with recent reports [39,40] showing that the progression
of early precancerous lesions (in the colon and else-
where) is curbed by cell cycle checkpoints that are acti-
vated by DNA replication “stress.” The precise nature of
this stress is currently unclear, but it is probably initiated
by increased expression of or gain-of-function mutations
involving oncogenes (e.g., CCN1, KRAS, or MYC), which
are known to be early events in tumorigenesis. Abnormal
activation of the prereplicative complex entails upregula-
tion of CDC6 and several minichromosome maintenance
genes. (Our data and those described by Freeman et al.
[41] might reflect an early step in this type of replicative
stress.) This process is associated with stalling and/or
collapse of replication forks and double-strand breaks,
which slow or arrest the cell cycle to allow the DNA to
be repaired (e.g., via homologous recombination). Activa-
tion of base excision repair suggests that DNA base oxi-
dation or deamination may also be accelerated in early
preinvasive lesions. Paradoxically, each of these repair
processes can per se cause genomic instability [40,42].
This would favor the onset and selection of loss-of-
function mutations involving tumor suppressor genes,
whose protein products drive the cell cycle checkpoints
(e.g., TP53, which is often mutated in the later phases of
colorectal tumorigenesis [1]), and the result would be un-
restrained tumor progression.
In line with the above findings, two other pathways
also appeared to be upregulated in our SPLs and LPLs.
The BIOCARTA ARF PATHWAY emanates from the
tumor suppressor proteins p16INK4a and p14ARF (both
encoded by CDKN2A). It is a key sensor of oncogenic
stress (e.g., the KRAS- or MYC-associated hyperproli-
ferative signal documented in colorectal adenomas). Ac-
tivation of the ARF pathway stabilizes TP53, thereby
promoting effective checkpoint activity [43]. Both classes
of preinvasive lesions also displayed upregulated nucleo-
tide excision repair (KEGG NUCLEOTIDE EXCISION
REPAIR), which targets UV- and carcinogen-induced
DNA adducts [44]. In conditions of replicative stress,
sustained activation of this pathway might be triggered
by the complex (but poorly defined) mixture of putative
(See figure on previous page.)
Figure 2 Hierarchical clustering and PCA of data sets based on cell cycle gene expression. Heat maps in panels A, B, and C show
expression levels for the Biocarta cell cycle pathway’s 22 gene components (listed on the right) across samples in the 3 tumor-stage-specific data
subsets: SPLs, LPLs, and CRCs, respectively (each containing corresponding samples of normal mucosa, N). Actual sample labels are shown at the
top of each heat map (0=normal mucosa; 1=tumor); the groups identified by hierarchical clustering analysis are separated by vertical white lines.
(Dendrograms are not shown.) (D) Bi-dimensional projection via PCA of all tumors and normal mucosal specimens using expression levels for the
22 cell cycle-related genes. Each dot represents a tissue sample (pink circle: N; yellow star: SPL; green diamond: LPL; blue square: CRC). The first
two components, PC1 and PC2, account for 81% of the variance in this set.
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carcinogens generated in the colorectum by host and
bacterial metabolism.
DNA damage checkpoints and apoptosis appear to be
efficient barriers that can restrain tumor growth for up
to two decades [45]. Nonetheless, DNA replication stress
and repair are naturally associated with increased cell
proliferation rates in colorectal tumors. The need for
DNA building blocks, before and after these barriers
have been disrupted, explains why nucleotide metabol-
ism is increased throughout tumorigenesis, as reflected
by the early persistent upregulation we observed in the
REACTOME PURINE RIBONUCLEOSIDE MONO-
PHOSPHATE BIOSYNTHESIS pathway and also by that
of the KEGG PYRIMIDINE METABOLISM pathway.
(The significance of the latter upregulation was border-
line, so it is not listed in Table 2.)
DNA replication is followed by dramatic changes in
the nucleus and its membrane during mitosis, so it was
not surprising that the RAN/mitotic spindle pathway
(BIOCARTA RANMS PATHWAY) was upregulated at
all three stages of tumorigenesis. The small nuclear
GTPase RAN (ras-related nuclear protein) directs the
assembly of the mitotic spindle and later that of the nu-
clear envelope, whose nuclear pore complexes are neces-
sary to re-establish nucleocytoplasmic transport [46].
Pathways involved in the G2-to-M transition of the cell
cycle (e.g., REACTOME CYCLIN A1 ASSOCIATED
EVENTS DURING G2 M TRANSITION) were also
constantly upregulated during tumorigenesis, as was the
REACTOME FORMATION OF TUBULIN FOLDING
INTERMEDIATES BY CCT TRIC pathway, which is
involved in protein folding mediated by the chaperonin
containing the TCP1 complex. This complex plays cen-
tral roles in the folding and assembly of numerous pro-
teins [47], so the upregulated expression of several genes
encoding its subunits could be easily ascribed to
increased protein metabolism in tumor cells.
Of the 23 pathways selectively upregulated in CRCs, six
pointed to the activation of the G1-to-S phase transition:
SA REG CASCADE OF CYCLIN EXPR (Regulatory cas-
cades of cyclin expression), BIOCARTA SKP2E2F PATH-
WAY, BIOCARTA CELLCYCLE PATHWAY, BIOCARTA
P27 PATHWAY, REACTOME G1 PHASE, and BIO-
CARTA RB PATHWAY (see also first section of Results
and Discussion). The simultaneous upregulation of these
inter-related cell-cycle pathways in advanced colorectal
tumors reflects the sustained proliferation that is a funda-
mental trait of cancer cells [48]. The invasive stages of
tumorigenesis are thought to be characterized by muta-
tions involving tumor suppressor genes like TP53 or
PTEN, alterations that allow cancer cells to circumvent
programs that limit proliferation (e.g., the cell-cycle check-
points, which operate more efficiently in early-stage
tumors, as discussed above). This high-proliferation envir-
onment is naturally associated with increased transcrip-
tion and translation, as documented in our dataset by the
upregulation of diverse RNA polymerase II and III func-
tions, amino-acid transport across the plasma membrane,
and tRNA aminoacylation (Table 2).
(See figure on previous page.)
Figure 3 Dysregulation of the cell cycle pathway during tumor progression. Expression levels for the 22 Biocarta cell cycle genes in each
tumor stage-specific data subset―SPLs (A), LPLs (B), and CRCs (C)―were compared with those in the normal mucosa (N) data set using
two-sample t-test. Each graph contains 22 nodes representing the genes in the pathway (white, yellow, and blue rectangles, and yellow ellipses)
plus a node for each tumor-stage being analyzed (green rectangles; those outlined in red represent the stage considered in the panel). Yellow
and blue rectangles: genes displaying tumor-associated upregulation or downregulation, respectively, in the stage represented in the panel;
white rectangles: genes that were also dysregulated in at least one of the other two stages; yellow ellipses: cell-cycle genes that displayed no
tumor-related dysregulation at any of the three stages. The connection matrix used for the graph was a sparse square matrix of order 25 where
1 indicates connection between nodes and 0 indicates no connection. Black lines: connection between a gene node and tumor-stage node
(i.e., tumor-related up- or downregulation of the gene at that stage).
Table 4 Numbers of pathways displaying significant
tumor-associated dysregulation in RS analysis and GSEA
of the N vs SPL, N vs LPL, and N vs. CRC data sets
Differential regulation in tumors † RS GSEA Overlap‡
No. pathways up-regulated in SPLs 23 75 21 (91%)*
No. pathways down-regulated in SPLs 41 121 37 (90%)*
No. pathways up-regulated in LPLs 21 75 20 (95%)*
No. pathways down-regulated in LPLs 29 109 26 (90%)*
No. pathways up-regulated in CRCs 33 52 16 (49%)**
No. pathways down-regulated in CRCs 25 42 21 (84%)*
† No. of pathways found dysregulated by RS and GSEA with p-values < 0.05.
‡ No. (%) of pathways identified as dysregulated in RS analysis that were
found to be similarly dysregulated in GSEA; asterisks indicate p-values
computed by Fisher’s exact test: *p=0; **p=1.1x10.-12.
Table 5 Numbers of pathways displaying significant
tumor-associated dysregulation in RS analysis of the N vs
CRC data set and in independent validation data sets I
and II
Differential
regulation
in CRCs †
N vs
CRC
V-set
I
V-set
II
Overlap‡
N vs CRC
and V-set I
N vs CRC
and V-set II
No. upregulated
pathways
33 107 157 24 (73%) -
*1.1x10-16
27 (82%) -
*3.3x10-16
No. downregulated
pathways
25 73 58 14 (56%) -
*4.6x10-10
9 (36%) -
*1.1x10-8
† No. of pathways found dysregulated by RS with p-values < 0.05.
‡ No. (%) of pathways dysregulated in N vs. CRC data set that were similarly
dysregulated in the indicated V-set.
* p-values computed by Fisher’s exact test.
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Over the past 20 years, important roles have emerged
for nonepithelial cells in the progression of colorectal
adenocarcinomas (and those involving other organs)
[48]. Macrophages, for example, seem to play conflicting
(but nonetheless crucial) roles in both tumor develop-
ment and metastasis [49], and this is consistent with the
marked upregulation of the BIOCARTA MONOCYTE
PATHWAY observed in our CRC dataset. Monocyte
differentiation gives rise to tumor-antagonizing and
tumor-promoting macrophages. The latter cells promote
angiogenesis, enhance tumor cell migration and invasion,
and suppress antitumor immunity [49]. CRC-related
upregulation of the BIOCARTA SET PATHWAY reflects
the importance of another stromal contribution to colo-
rectal carcinogenesis: granzyme release by cytotoxic T
lymphocytes. These serine proteases (along with the mul-
tiprotein SET complex, whose components are encoded
by genes frequently upregulated in our tumors) trigger
apoptosis and are therefore regarded as mediators of
antitumor immunity [50]. But they can also provoke in-
flammation and cleave extracellular matrix components
[50]. Moreover, the SET protein is believed to act as an
oncoprotein (given its apoptosis-inhibiting activity within
the SET complex) and as a regulator of chromatin re-
modeling [51,52]. On the basis of our transcriptomic data
alone, it is difficult to discern what type of impact SET
pathway activation has on colorectal cancer progression.
Finally, the REACTOME GLYCOLYSIS pathway was
found to be upregulated in CRCs. Since its first descrip-
tion in 1924 by Otto Warburg [53], aerobic glycolysis
has been considered the preferred pathway for metabol-
izing glucose in cancer cells (as opposed to the oxidative
metabolism used by normal differentiated cells). Our
data demonstrate that the switch to aerobic metabolism
can be documented with transcriptional analysis of the
genes encoding metabolic enzymes. Cancer cells appear
to exploit aerobic glycolysis to produce the biomass
needed for new cells, despite the pathway’s inefficient
ATP generation [54]. Cancer cells’ need for nutrients to
fuel biomass production is also reflected in the activa-
tion of other pathways mentioned above, such as those
involving glucose and amino-acid transport, regulation
of glucokinase, and purine biosynthesis.
Conclusions
Our exhaustive description of the sequence of critical
molecular events characterizing the progression of colo-
rectal tumors is based on a statistically robust analysis of
transcriptomic data carried out at the level of functional
molecular processes rather than individual genes or pro-
teins. This analysis revealed specific pathways whose
dysregulation might play a role in each transition of the
transformation process. This is the first study in which
such an approach has been used to gain further insights
into colorectal tumorigenesis. Therefore, our findings
provide a foundation for larger projects in which tran-
scriptomic data will be integrated with (epi)genomic,
proteomic, and metabolomic data from ongoing and fu-
ture studies. They should open roads to experimental re-
search aimed at providing more in-depth, systems-level
understanding of colorectal tumorigenesis.
Additional file
Additional file 1: Biological pathways found to be downregulated
at different stages of colorectal transformation (Table 3 and
Figure 4).
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Figure 4 Overview of tumor-related pathway dysregulation at different stages of transformation. Pathways displaying identical
configurations of dysregulation (e.g., upregulated in SPLs and LPLs but not CRCs) have been combined into 10 more general biological groups
(white boxes). Arrows indicate type (up vs. down) of dysregulation.
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